Population pharmacokinetic and concentration-QTc models for moxifloxacin: Pooled analysis of 20 thorough QT studies

Journal of Clinical Pharmacology

Volumn 51, Issue 8, 2011, Pages 1152-1162

  Florian, Jeffry A ^a   Tornøe, Christoffer W ^a   Brundage, Richard ^b   Parekh, Ameeta ^a   Garnett, Christine E ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

exposure response modeling; ICH E14; moxifloxacin; Population pharmacokinetics; QT prolongation; thorough QT studies

Indexed keywords

MOXIFLOXACIN; PLACEBO;

ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; ENCAPSULATION; HUMAN; HYSTERESIS; INTESTINE TRANSIT TIME; MAXIMUM PLASMA CONCENTRATION; QT INTERVAL; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; DRUGS, INVESTIGATIONAL; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; QUINOLINES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 79960602475     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010381498     Document Type: Article

References (26)

1. E14: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs questions & answers. 2008. www.ich.org. Accessed November 1, 2010.
2. Fridericia LS. Die Systolendauer im Elektrokardiogramm bei normalen Menschen und bei Herzkranken. Acta Med Scand. 1920 ; 53: 469-486
3. Garnett CE, Beasley N, Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008 ; 48: 13-18 (Pubitemid 350292272)
4. Bloomfield D, Kost J, Ghosh K, et al. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008 ; 84: 475-480
5. Dixon R, Job S, Oliver R, et al. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. Br J Clin Pharmacol. 2008 ; 66: 396-404
6. Iwamoto M, Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol. 2008 ; 48: 726-733 (Pubitemid 351713160)
7. Kubitza D, Mueck W, Becka M. Randomized, double-blind, crossover study to investigate the effect of rivaroxaban on QT-interval prolongation. Drug Saf. 2008 ; 31: 67-77
8. Zhang J. Testing for positive control activity in a thorough QTc study. J Biopharm Stat. 2008 ; 18: 517-528 (Pubitemid 351891688)
9. Malik M, Hnatkova K, Schmidt A, Smetana P. Electrocardio-graphic QTc changes due to moxifloxacin infusion. J Clin Pharmacol. 2009 ; 49: 674-683
10. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007 ; 34: 711-726 (Pubitemid 47477040)
11. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn. 2001 ; 28: 231-252 (Pubitemid 32643366)
12. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci. 2002 ; 4: E27
13. Tornoe CW, Garnett CE, Wang Y, Li M, Florian JR, Gobburu JV. Creation of an automated thorough QT data analysis, repository and reporting tool for regulatory review. J Clin Pharmacol. 2010 ;:
14. Holford NH, Coates PE, Guentert TW, Riegelman S, Sheiner LB. The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration-effect relationships. Br J Clin Pharmacol. 1981 ; 11: 187-195 (Pubitemid 11167986)
15. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther. 1979 ; 25: 358-371 (Pubitemid 9164953)
16. Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008 ; 52: 852-857 (Pubitemid 351358362)
17. Simon N, Sampol E, Albanese J, et al. Population pharmacokinetics of moxifloxacin in plasma and bronchial secretions in patients with severe bronchopneumonia. Clin Pharmacol Ther. 2003 ; 74: 353-363 (Pubitemid 37222856)
18. Mason JW, Moon TE, Florian JA, Garnett CE, Spaulding RR, Selness DS. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies. J Clin Pharmacol. :
19. Yan LK, Zhang J, Ng MJ, Dang Q. Statistical characteristics of moxifloxacin-induced QTc effect. J Biopharm Stat. 2010 ; 20: 497-507
20. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006 ; 440: 463-469
21. Staudacher I, Schweizer PA, Katus HA, Thomas D. hERG: protein trafficking and potential for therapy and drug side effects. Curr Opin Drug Discov Devel. 2010 ; 13: 23-30
22. Dennis A, Wang L, Wan X, Ficker E. hERG channel trafficking: novel targets in drug-induced long QT syndrome. Biochem Soc Trans. 2007 ; 35: 1060-1063 (Pubitemid 350206429)
23. Kuryshev YA, Ficker E, Wang L, et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. J Pharmacol Exp Ther. 2005 ; 312: 316-323 (Pubitemid 40096484)
24. Lettieri J, Vargas R, Agarwal V, Liu P. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers. Clin Pharmacokinet. 2001 ; 40 (suppl 1). 19-25 (Pubitemid 32295678)
25. Benton RE, Sale M, Flockhart DA, et al. Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther. 2000 ; 67: 413-418 (Pubitemid 30246819)
26. Rodriguez I, Kilborn MJ, Liu XK, et al. Drug-induced QT prolongation in women during the menstrual cycle. JAMA. 2001 ; 285: 1322-1326 (Pubitemid 32216147)